Literature DB >> 18703110

A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

S D Klas1, C R Petrie, S J Warwood, M S Williams, C L Olds, J P Stenz, A M Cheff, M Hinchcliffe, C Richardson, S Wimer.   

Abstract

Here we confirm that intranasal (IN) dry powder anthrax vaccine formulations are able to protect rabbits against aerosol challenge 9 weeks after a single immunization. The optimum dose of rPA in our dry powder anthrax vaccine formulation in rabbits was experimentally determined to be 150microg and therefore was chosen as the target dose for all subsequent experiments. Rabbits received a single dose of either 150microg rPA, 150microg rPA+150microg of a conjugated 10-mer peptide representing the Bacillus anthracis capsule (conj), or 150microg of conj alone. All dry powder formulations contained MPL and chitosan (ChiSys). Significant anti-rPA titers and anthrax lethal toxin neutralizing antibody (TNA) levels were seen with both rPA containing vaccines, although rPA-specific IgG and TNA levels were reduced in rabbits immunized with rPA plus conj. Nine weeks after immunization, rabbits were exposed to a mean aerosol challenge dose of 278 LD50 of Ames spores. Groups immunized with rPA or with rPA+conj had significant increases in survivor proportions compared to the negative control group by Logrank test (p=0.0001 and 0.003, respectively), and survival was not statistically different for the rPA and rPA+conj immunized groups (p=0.63). These data demonstrate that a single immunization with our dry powder anthrax vaccine can protect against a lethal aerosol spore challenge 9 weeks later.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703110      PMCID: PMC2742988          DOI: 10.1016/j.vaccine.2008.07.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  56 in total

Review 1.  Chitosan for mucosal vaccination.

Authors:  I M van der Lubben; J C Verhoef; G Borchard; H E Junginger
Journal:  Adv Drug Deliv Rev       Date:  2001-11-05       Impact factor: 15.470

Review 2.  Intranasal delivery of vaccines against HIV.

Authors:  Michael Vajdy; Manmohan Singh
Journal:  Expert Opin Drug Deliv       Date:  2006-03       Impact factor: 6.648

3.  Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.

Authors:  S F Little; B E Ivins; W M Webster; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2005-12-27       Impact factor: 3.641

4.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Authors:  Joanne Huang; John A Mikszta; Matthew S Ferriter; Ge Jiang; Noel G Harvey; Beverly Dyas; Chad J Roy; Robert G Ulrich; Vincent J Sullivan
Journal:  Hum Vaccin       Date:  2007-05-13

6.  Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.

Authors:  S F Little; B E Ivins; W M Webster; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2007-01-02       Impact factor: 3.641

7.  Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.

Authors:  Brian R Sloat; Zhengrong Cui
Journal:  J Pharm Pharmacol       Date:  2006-04       Impact factor: 3.765

8.  Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae.

Authors:  H Y Wu; M H Nahm; Y Guo; M W Russell; D E Briles
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

9.  Anthrax vaccine powder formulations for nasal mucosal delivery.

Authors:  Ge Jiang; Sangeeta B Joshi; Laura J Peek; Duane T Brandau; Juan Huang; Matthew S Ferriter; Wendy D Woodley; Brandi M Ford; Kevin D Mar; John A Mikszta; C Robin Hwang; Robert Ulrich; Noel G Harvey; C Russell Middaugh; Vincent J Sullivan
Journal:  J Pharm Sci       Date:  2006-01       Impact factor: 3.534

10.  A dually active anthrax vaccine that confers protection against both bacilli and toxins.

Authors:  Gi-Eun Rhie; Michael H Roehrl; Michael Mourez; R John Collier; John J Mekalanos; Julia Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more
  11 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Laser vaccine adjuvant for cutaneous immunization.

Authors:  Xinyuan Chen; Mei X Wu
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 3.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

4.  A novel laser vaccine adjuvant increases the motility of antigen presenting cells.

Authors:  Xinyuan Chen; Pilhan Kim; Bill Farinelli; Apostolos Doukas; Seok-Hyun Yun; Jeffrey A Gelfand; Richard R Anderson; Mei X Wu
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

5.  Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.

Authors:  Sachin G Thakkar; Zachary N Warnken; Riyad F Alzhrani; Solange A Valdes; Abdulaziz M Aldayel; Haiyue Xu; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2018-10-16       Impact factor: 9.776

6.  The Combinations Chitosan-Pam3CSK4 and Chitosan-Monophosphoryl Lipid A: Promising Immune-Enhancing Adjuvants for Anticaries Vaccine PAc.

Authors:  Yongli Bi; Qingan Xu; Lingkai Su; Jiantao Xu; Zhongfang Liu; Ying Yang; Hua Tang; Yuhong Li; Mingwen Fan
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

Review 7.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

8.  Application of quality by design approach to optimize process and formulation parameters of rizatriptan loaded chitosan nanoparticles.

Authors:  Ajinath Eknath Shirsat; Sohan S Chitlange
Journal:  J Adv Pharm Technol Res       Date:  2015 Jul-Sep

Review 9.  Chitosan-based mucosal adjuvants: Sunrise on the ocean.

Authors:  Yufei Xia; Qingze Fan; Dongxia Hao; Jie Wu; Guanghui Ma; Zhiguo Su
Journal:  Vaccine       Date:  2015-08-10       Impact factor: 3.641

10.  Achieving consistent multiple daily low-dose Bacillus anthracis spore inhalation exposures in the rabbit model.

Authors:  Roy E Barnewall; Jason E Comer; Brian D Miller; Bradford W Gutting; Daniel N Wolfe; Alison E Director-Myska; Tonya L Nichols; Sarah C Taft
Journal:  Front Cell Infect Microbiol       Date:  2012-06-13       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.